Performance of immuno - positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 2133-2140

  Börjesson, Pontus K E ^a   Jauw, Yvonne W S ^a   Boellaard, Ronald ^a   De Bree, Remco ^a   Comans, Emile F I ^a   Roos, Jan C ^a   Castelijns, Jonas A ^a   Vosjan, Maria J W D ^a   Kummer, J Alain ^a   Leemans, C René ^a   Lammertsma, Adriaan A ^a   Van Dongen, Guus A M S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY U36; UNCLASSIFIED DRUG; ZIRCONIUM;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEASIBILITY STUDY; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; NECK DISSECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

AGED; ANTIBODIES, MONOCLONAL; CARCINOMA, SQUAMOUS CELL; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; ISOTOPE LABELING; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK DISSECTION; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; SENSITIVITY AND SPECIFICITY; ZIRCONIUM;

EID: 33646241548     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2137     Document Type: Article

References (23)

1. Zuckier LS, DeNardo GL. Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med 1997;27:10-29.
2. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003;52:281-96.
3. 99mTc-labeled monoclonal antibody U36 in patients with head and neck cancer. Clin Cancer Res 1995;1:591-8.
4. 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. J Nucl Med 2000;41:1999-2010.
5. 186Re-labeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clin Cancer Res 2002;8:3401-6.
6. Eary JF. PET imaging for planning cancer therapy. J Nucl Med 2002;42:764-9.
7. Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003;44:1271-81.
8. Verel I, Visser GWM, Van Dongen GAMS. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005;46:164-71S.
9. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003;44:1271-81.
10. 90Y-labeled monoclonal antibodies. J Nucl Med 2003;44:1663-70.
11. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS. Clinical screening of monoclonal antibodies 323/A3 (K931), cSF-25 (K984), and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nucl Med Commun 1994;15:613-27.
12. Sobin LH, Wittekind Ch, editors. TNM classification of malignant tumors 6th edition. International Union Against Cancer New York: Wiley-Liss; 2002
13. Heider KH, Mulder JW, Ostermann E, et al. Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys. Eur J Cancer 1995;31A:2385-91.
14. Van den Brekel MWM, Stel HV, Castelijns JA, et al. Cervical lymph node metastases: assessment of radiological criteria. Radiology 1990;177:379-84
15. Robbins KT, Clayman G, Levine PA, et al. American Head and Neck Society: American Academy of Otolaryngology and Head and Neck Surgery. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology and Head and Neck Surgery. Arch Otolaryngol Head Neck Surg 2002;128:751-8
16. Marsden PK, Strul D, Keevil SF, Williams SCR, Cash D. Simultaneous PET and NMR. Br J Radiol 2002;75:S53-9.
17. 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 2002;24:345-9.
18. 18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior. Eur Arch Otorhinolaryngol 2004;261:479-83
19. De Bree R, Roos JC, Quak JJ, et al. Selection of monoclonal antibody E48 IgG or U36 for adjuvant therapy in head and neck cancer patients. Br J Cancer 1997;75:1049-60.
20. Regelink G, Brouwer J, De Bree R, et al. Detection of unknown primary tumors and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging 2002;29:1024-30.
21. Birchler MT, Milisavlijevic D, Pfaltz M, et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope 2003;113:1231-7.
22. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-46.
23. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003;9:571-9.